Publications by authors named "Paulina Brożek"

3 Publications

  • Page 1 of 1

Quality of life in survivors of childhood brain tumour and the association of children's diseases on quality of their parents life.

Psychooncology 2019 05 11;28(5):1088-1095. Epub 2019 Apr 11.

Department of Pediatric Oncology, Hematology and Chemotherapy, Medical University of Silesia, Katowice.

Objective: Evaluation of children's quality of life (QoL) after finished brain tumour treatment and the association of children's diseases on quality of their parents' life.

Methods: The study group was consisted of 46 children after brain tumour treatment (aged 4, 5, to 29 years old). The control group was composed of 104 students of primary, secondary, and high schools. One hundred fifty (104 + 46) parents were included in the study. Standardised QoL questionnaires (PEDsQL-4.0, WHOQOL-BREF) were used. Survivors' QoL was assessed from patients' and their parents' point of view, also the association of children's diseases on quality of their parents' life was estimated.

Results: QoL of children after brain tumour treatment was lower than in the control group according to the children (P < 0.001) and their parents (P < 0.001). The survivors worst rated their ability to social functioning (P < 0.0010) and physical functioning (P < 0.001) in comparison with self-assessment of healthy children. According to their parents, the functioning of children in all zones was worse than in the control group, mostly in social (P < 0.001) and physical sphere (P < 0.001), too. QoL of children with low-grade tumour was comparable with QoL of children with high-grade tumour). QoL of survivors' caregivers in study was higher than QoL of parents of control groups (P = 0.023).

Conclusions: The quality of patients' life after brain tumour treatment is lower in comparison with healthy children. QoL of the parents of survivor is higher than the QoL of healthy children parents. The assessment of QoL of children after brain tumour treatment should be an inherent element of health monitoring.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
May 2019

[Difficulties of the therapy in a boy with coexisting type 1 diabetes mellitus and idiopathic thrombocytopenic purpura].

Pediatr Endocrinol Diabetes Metab 2017 ;23(3):165-168

Klinika Diabetologii Dziecięcej Śląskiego Uniwersytetu Medycznego.

Idiopathic thrombocytopenic purpura (ITP) is an acquired autoimmune disease, caused by antibodies against platelet glycoproteins, which provoke platelet destruction and inhibit platelet production in bone marrow. Type 1 Diabetes Mellitus (T1DM) is an acquired autoimmune disease in witch beta cells are destroyed by autoantibodies. Patient with T1DM since the age of 6, was treated by intensive functional insulin therapy by insulin pump. At the age of 14,5 he was also diagnosed with ITP. Due to the short effect of immunoglobulin therapy, glucocorticoids were introduced. After 3 months of glucocorticotherapy the platelet count was 46 G/l. Patient developed various adverse effects of glucocorticoids, among others stretch marks covering all surface of his abdomen, buttocks, arms and thighs and raise in the daily requirement of insulin by 200%. Adverse effects of glucocorticotherapy made impossible the therapy by insulin pump and imposed urgent revision of the ITP therapy. Side effects of the glucocorticotherapy can make impossible the treatment by insulin pump of T1DM in children.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
July 2018

Depression, sleep disturbances and anxiety in patients with relapsing-remitting multiple sclerosis: a longitudinal cohort observation.

Psychiatr Danub 2017 Sep;29(Suppl 3):464-468

Department of Neurology, Medical University of Silesia, Medical School in Katowice, XXV-lecia str. 12A/2, 58-260 Bielawa, Poland,

Background: Depression, sleep disturbances and anxiety may affect almost half of the population of patients with multiple sclerosis (MS) and they are major determinants of poor quality of life in young adults. The aim of our study was to assess their incidence in patients with MS in Poland, and whether they change during longitudinal observation in routine clinical practice.

Subjects And Methods: We included 53 consecutive patients with relapsing-remitting form of MS in this prospective study, who were treated in our department. All patients were examined at the entry to the study and after at least three or more years after study start with 4 standardized questionnaires and clinical scales that were validated in Polish patients: Athens Insomnia Scale (AIS), Epworth Sleepiness Scale (ESS), Hospital Anxiety and Depression Scale (HADS) and Expanded Disability Status Scale (EDSS). The data from the two time-points were compared.

Results: At the entry to the study daytime sleepiness, nighttime insomnia, depression episodes and anxiety were observed in 11.3%, 13.2%, 11.3% and 28.3% of patients, respectively. At the end of the study higher proportion of patients reported any form of drowsiness, depression, insomnia or anxiety, however, the differences were not statistically significant. Except for anxiety, higher proportion of patients reported definite disorders, with the rise from 3.8% to 13.2% having depression and rise from 9.4% to 15.1% having insomnia. Moderate or pathological drowsiness was not reported initially, but it was reported in 5% and 2.5% patients, respectively, at the study end.

Conclusions: The incidence of sleep and mood disturbances in polish patients with MS is quite high, and it is comparable to other studies in patients with MS. Possible mood changes or sleep disturbances in individual patients should be routinely monitored by clinicians.
View Article and Find Full Text PDF

Download full-text PDF

September 2017